Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

LianBio in $200 Million Deal for China/Asia Rights to Tarsus Ophthalmology Drug

publication date: Mar 29, 2021

LianBio, a Shanghai-Princeton in-licensing company, formed a $200 million partnership with Tarsus Pharma of Irvine, CA, to develop Tarsus' ophthalmology drug in Greater China. Tarsus describes TP-03 as a first-in-class therapeutic in late-stage development to treat Demodex blepharitis and Meibomian Gland Disease (MGD), two eye conditions with unmet treatment needs. The company said there are 40 million China patients with Demodex blepharitis and another 70 million patients with MGD. Tarsus will receive a minority stake in LianBio Ophthalmology, a newco, if specified milestones are met. More details....

Stock Symbol: (NSDQ: TARS)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.